

Mundipharma signs a deal with Grünenthal

January 16, 2018 | News

Mundipharma will market and distribute Grünenthal's Tramal (tramadol) in China from May 1, 2018.



Mundipharma has entered into a license and distribution agreement with the science-based pharmaceutical company Grünenthal, specialized in pain, gout and inflammation. As per the agreement, Mundipharma will market and distribute Grünenthal's Tramal (tramadol) in China from May 1, 2018.

Tramal is a well-established analgesic for the treatment of moderate to severe pain. It is the only international brand of tramadol in China that includes sustained release tablets and immediate release capsules, as well as an intravenous formulation used for post-operative pain in patient controlled intravenous analgesia (PCIA). Delivering the analgesic intravenously with a patient-controlled device can provide an important and effective pain control option for patients.

Both organisations are committed to ensuring the responsible use of analgesic medications to treat post-operative patients when other options provide insufficient relief.

The Grünenthal Group intends to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company.